Transcatheter aortic valve implantation (TAVI) has been approved in Europe since 2007, whereas these devices are just entering large-scale research trials in the United States. Dr. Popma leads a panel discussion with European interventionalist Dr. Eberhard Grube and surgeon Dr. Neil Moat on their experiences with TAVI.
Given SYNTAX, is left main stenting ready for primetime? Do the NCDR data lay to rest DES safety concerns? Recorded at EuroPCR 2009, Dr. Popma discusses the current status and future roles of PCI and DES with Drs.Gershlick and Tamburino.
When choosing between DES and BMS or among the various DES, how much weight should be given to 1-year data vs the totality of evidence? What is the duration of stent thrombosis risk? Dr. Leon leads a panel discussion to address these issues with Drs. Kandzari and Yeung.
Learn about the current status of less-invasive strategies to repair thoracic aneurysms as Dr. Mack leads a discussion with vascular surgeons, Drs. Kasirajan and Woo. Which cases are amenable to endovascular repair and which require open surgery?
On February 3, 2009, the FDA's Cardiovascular and Renal Drugs Advisory Committee unanimously voted to recommend approval of the novel thienopyridine prasugrel for use in ACS patients undergoing PCI. Drs. Nissen, Ohman, Kandzari, Topol, and Steg each give their take on the likely implications for clinical practice and remaining issues of concern in the optimal management of patients with ACS.
Provisional T-stenting, crush, or culotte? Which is the best way to tackle bifurcation lesions? Dr Hildick-Smith presents an overview including the results of his TCT 2008 late-breaking BBC-ONE trial.
Will SYNTAX and HORIZONS-AMI change the role of DES in multivessel disease and AMI? Recorded at TCT 2008, Drs Kandzari and Bhatt each lead a case-based discussion with Drs Feres and Meredith that draws upon the latest data including these major trials.
Since our last quiz, COURAGE QoL was published, the SYNTAX trial was released... Have you been paying attention? Take our interventional cardiology quiz and find out how you rate.
As the COURAGE debate rages on, PCI and DES next tackle bypass surgery in patients with diabetes, multivessel disease and left main lesions. From ESC in Munich, Dr Boden joins SYNTAX investigators Drs Mohr and Serruys to discuss PCI and CABG in complex patients given the SYNTAX findings.
Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs Gilles Montalescot and Johanne Silvain as they discuss a case of bleeding and review treatment strategies to improve outcomes and minimize adverse events for these patients.
Just when you thought it was safe to go back into the cath lab, COURAGE roars again. In light of quality of life data showing that the early benefits for PCI are lost at two to three years, Drs Kandzari and Popma discuss how to optimally manage patients with stable angina.
Traditionally, Latin American countries have had lower rates of PCI and DES use compared with Europe and the US. Recorded at SOLACI 2008, Dr Leon leads an information exchange on PCI north and south of the border with Drs Abizaid, Belardi, Echeverri and Lopez-Cuellar.
Acknowledgements
CME provider: Medscape.
The drug-eluting stents theme is supported by an independent educational grant from Medtronic, Inc., Daiichi Sankyo, Inc., and Eli Lilly & Co.
Steering committee
The steering committee members are active in overseeing the development and direction of this educational series.